Supplementary Appendix
|
|
|
- Bertha O’Connor’
- 6 years ago
- Views:
Transcription
1 Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368: DOI: /NEJMoa
2 The authors would like to express their gratitude to the investigators who made this study possible. ABT-450 was identified as a lead compound by Abbott and Enanta Pharmaceuticals. 1
3 Table of Contents Virologic Stopping Rules Page 3 Figure S1A Page 4 Figure S1B Page 5 Figure S1C Page 6 Figure S1D Page 7 Table S1 Page 8 2
4 Virologic Stopping Rules: Patients were required to stop study drug treatment if they met any of the following criteria: failure to achieve 2 log 10 IU/mL HCV RNA decrease at week 1, confirmed HCV RNA increase from nadir >0.5 log 10 IU/mL at any time, failure to achieve undetectable HCV RNA at week 6, or confirmed detectable HCV RNA at any point after undetectable HCV RNA. These criteria were selected to minimize ongoing viral replication in the presence of direct-acting antivirals, which could increase the risk for selection of resistant variants and compromise future treatment options. Failure to achieve a 2 log 10 IU/mL reduction in the first week of dosing with an ABT-450/r-containing regimen would be strong evidence of inadequate viral suppression. Likewise, any confirmed increase in HCV RNA beyond that attributable to assay variability (approximately 0.5 log 10 IU/mL), or any detectable HCV RNA after 6 weeks of study drug dosing, were considered presumptive evidence of ongoing viral replication in the presence of non-suppressive antiviral drug concentrations. 3
5 Figure S1A. Enrollment of Patients 94 Patients Screened 50 Patients Enrolled 44 Patients Failed Screening: 36 patients did not satisfy inclusion/exclusion criteria 6 patients withdrew consent 2 patients were not enrolled since enrollment ended 19 Patients Enrolled in Arm 1 14 Patients Enrolled in Arm 2 17 Patients Enrolled in Arm 3 18 Patients Completed Study Drug 1 patient discontinued due to ALT elevation 13 Patients Completed Study Drug 1 patient discontinued due to inability to comply with study drug regimen 17 Patients Completed Study Drug 6 patients rebounded 3 patients relapsed 4
6 Figure S1B. Individual HCV RNA Values through 12 Weeks of Treatment and 36 Weeks of Post-Treatment Follow-up in Arm 1 IL28B CC CC CC CC CC CC CC CC CC CC CT CT CT CT CT CT CT TT TT Genotyp 1a 1a 1a 1a 1a 1a 1a 1a 1a 1a 1b 1a 1a 1b 1a 1a 1a 1a 1a BL 5.5x x x x x x x x x x x x x x x x x x x10 6 Wk <25 <25 U <25 <25 < <25 Wk 2 <25 <25 <25 58 <25 <25 <25 U U U U <25 <25 U U <25 U <25 U Wk 3 <25 <25 <25 <25 U U U U U U U U U U U U U U Wk 4 <25 U U U U U U U U U U U U U U U U U Wk 5 U U U U U U U U U U U U U U U U U U Wk 6 <25 U U U U U U U U U U U U U U U U U Wk 7 U U U U U U U U U U U U U U U U U U Wk 8 U U U U U U U U U U U U U U U U U U Wk 9 U U U U U U U U U U U U U U U U U U Wk 10 U U U U U U U U U U U U U U U U U U Wk 11 U U U U U U U U U U U U U U U U U U Wk 12 U U U U U U U U U U U U U U U U U PTW 2 U U U U U U U U U U U U U U U U U U PTW 4 U U U U U U U U U U U U U U U U U U PTW 8 U U U U U U U U U U U U U U U U U U PTW12 U U U U U U U U U U U U U U U U U U PTW24 U U U U U U U U U U U U U U U U U U PTW36 U U U U U U U U U U U U U U U U U U PTW48 U U U U U U U U U U U U U U U U U U U=Undetectable (HCV RNA not detected), <25 = <25 IU/mL (HCV RNA detected) 1 subject discontinued due to ALT elevation 5
7 Figure S1C. Individual HCV RNA Values through 12 Weeks of Treatment and 24 Weeks of Post-Treatment Follow-up in Arm 2 IL28B CC CC CC CC CC CT CT CT CT CT CT CT TT TT Genotype 1a 1a 1a 1b 1a 1a 1a 1a 1a 1a 1a 1b 1b 1a Baseline 2.3x x x x x x x x x x x x x x10 7 Wk 1 <25 U < < Wk 2 U U U <25 U <25 <25 <25 U <25 <25 52 U Wk 3 U U U U U U <25 <25 U U U 30 U Wk 4 U U U U U U <25 U U U U <25 U Wk 5 U U U U U U U U U U U U U Wk 6 U U U U U U U U U U U U U Wk 7 U U U U U U U U U U U U U Wk 8 U U U U U U U U U U U U U Wk 9 U U U U U U U U U U U U U Wk 10 U U U U U U U U U U U U U Wk 11 U U U U U U U U U U U 26 U Wk 12 U U U U U U U U U U U U U PTW 2 U U U U U U U U U U U U U PTW 4 U U U U U U U U U U U U U PTW 8 U U U U U U U U U U U U U PTW12 U U U U U U U U U U U U U PTW24 U U U U U U U U U U U U PTW36 U U U U U U U U U U U PTW48 U U U U U U U U U U U U=Undetectable (HCV RNA not detected), <25 = <25 IU/mL (HCV RNA detected) 1 subject discontinued due to noncompliance caused by personal issues 6
8 Figure S1D. Individual HCV RNA Values through 12 Weeks of Treatment and 12 Weeks of Post-Treatment Follow-up in Arm 3 IL28B CT CT CT CT CT CT CT* CT CT CT CT CT TT TT TT TT TT Genotype 1a 1a 1a 1a 1a 1a 1a 1b 1a 1a 1a 1a 1a 1a 1a 1a 1a Baseline 2.6x x x x x x x x x x x x x x x x x10 6 Wk <25 U < U Wk 2 U U <25 U U U U 37 U <25 <25 <25 <25 <25 <25 Wk 3 U 249 U U U U 570 <25 U U U U <25 <25 U U <25 Wk 4 U U U U U <25 U U U U <25 U U U U Wk 5 U U U U U U U U U 1990 U U U U Wk 6 U U U U U U U U U U U U Wk 7 U U U U U U U U U U U U U Wk 8 U U U U U U U U U U U U <25 Wk 9 U U U U U U U U U U U U 61 Wk 10 U U U U U U U U U U U U 4240 Wk 11 U U U U U U U U U U <25 U Wk 12 U <25 U U U U U U U U 861 U PTW U U 30 U U U U U U PTW U U U U U U U U PTW 8 U U U U U U U U PTW12 U U U U U U U U PTW24 U U U U U U U U PTW36 U U U U U U U U *Underdosed for first 3 weeks U=Undetectable (HCV RNA not detected), <25 = <25 IU/mL (HCV RNA detected) 7
9 Table S1. Treatment-Emergent Adverse Events (All) Arm 1 Arm 2 Arm 3 Treatment-naïve ABT-450/r 250/100 mg QD + ABT mg BID + RBV N=19 Treatment-naïve ABT-450/r 150/100 mg QD + ABT mg BID + RBV N=14 Non-responders ABT-450/r 150/100 mg QD + ABT mg BID + RBV N=17 Adverse Events Fatigue, n (%) 9 (47.4) 6 (42.9) 6 (35.3) Nausea 4 (21.1) 3 (21.4) 4 (23.5) Headache 5 (26.3) 2 (14.3) 3 (17.6) Dizziness 1 (5.3) 4 (28.6) 4 (23.5) Insomnia 5 (26.3) 3 (21.4) 0 Pruritus 4 (21.1) 0 2 (11.8) Rash 4 (21.1) 1 (7.1) 1 (5.9) Vomiting 1 (5.3) 3 (21.4) 0 Anemia 2 (10.5) 1 (7.1) 1 (5.9) Leukocytosis 0 1 (7.1) 0 Lymphadenopathy 0 1 (7.1) 0 Tachycardia 0 1 (7.1) 0 Ear Pain (5.9) Eye Haemorrhage (5.9) Lacrimation Increased 1 (5.3) 0 0 Photophobia 0 1 (7.1) 0 Abdominal Discomfort 1 (5.3) 0 1 (5.9) Abdominal Distension 0 1 (7.1) 0 Cheilitis (5.9) Constipation 2 (10.5) 0 0 Dental Caries 0 1 (7.1) 0 Diarrhea 2 (10.5) 1 (7.1) 2 (11.8) Dyspepsia 0 1 (7.1) 0 Epigastric Discomfort (5.9) 8
10 Flatulence 0 1 (7.1) 1 (5.9) Frequent Bowel Movements 1 (5.3) 0 0 Gastritis 1 (5.3) 0 0 Gastroesophageal Reflux Disease 2 (10.5) 0 0 Asthenia 1 (5.3) 0 0 Chest Pain 0 1 (7.1) 0 Chills (5.9) Energy Increased 0 1 (7.1) 0 Feeling Abnormal 1 (5.3) 0 0 Hunger (5.9) Influenza Like Illness 0 1 (7.1) 0 Injection Site Reaction (5.9) Irritability 1 (5.3) 2 (14.3) 1 (5.9) Non-Cardiac Chest Pain 1 (5.3) 0 0 Oedema Peripheral 3 (15.8) 1 (7.1) 0 Pain 2 (10.5) 0 0 Pyrexia (5.9) Hyperbilirubinaemia 1 (5.3) 0 0 Seasonal Allergy 1 (5.3) 0 0 Body Tinea 1 (5.3) 0 0 Bronchitis 1 (5.3) 0 0 Cellulitis 1 (5.3) 0 0 Folliculitis 0 1 (7.1) 0 Gastroenteritis (5.9) Hordeolum (5.9) Influenza (5.9) Pneumonia (5.9) Sinusitis 0 1 (7.1) 0 Tinea Pedis 0 1 (7.1) 0 Upper Respiratory Tract Infection 2 (10.5) 0 1 (5.9) Urinary Tract Infection 1 (5.3) 0 0 Viral Upper Respiratory 0 1 (7.1) 0 9
11 Tract Infection Laceration 0 1 (7.1) 0 Muscle Strain 0 1 (7.1) 0 Procedural Pain 0 1 (7.1) 0 Sunburn 0 1 (7.1) 0 Alanine Aminotransferase 1 (5.3) 0 1 (5.9) Increased Aspartate Aminotransferase 1 (5.3) 0 0 Increased Blood Creatinine Increased Blood Oestrogen Increased Creatinine Renal Clearance Decreased Electrocardiogram QT Prolonged 1 (5.3) (5.9) 1 (5.3) (5.3) 0 0 Heart Rate Increased 0 1 (7.1) 1 (5.9) Decreased Appetite 2 (10.5) 2 (14.3) 0 Diabetes Mellitus (5.9) Hyperglycaemia 1 (5.3) 0 0 Hypokalaemia (5.9) Arthralgia 1 (5.3) 2 (14.3) 0 Back Pain 2 (10.5) 1 (7.1) 1 (5.9) Flank Pain 2 (10.5) 0 0 Muscle Spasms 1 (5.3) 0 1 (5.9) Myalgia 0 1 (7.1) 1 (5.9) Pain in Extremity 0 1 (7.1) 0 Cognitive Disorder 0 1 (7.1) 0 Coordination Abnormal (5.9) Dysgeusia 1 (5.3) 1 (7.1) 1 (5.9) Hypoaesthesia 1 (5.3) 0 0 Lethargy (5.9) 10
12 Memory Impairment 1 (5.3) 0 0 Migraine (5.9) Paraesthesia 2 (10.5) 2 (14.3) 0 Poor Quality Sleep 0 2 (14.3) 0 Sinus Headache (5.9) Tremor 1 (5.3) 0 0 Abnormal Dreams 0 1 (7.1) 0 Affect Lability 1 (5.3) 0 0 Agitation 1 (5.3) 1 (7.1) 0 Anxiety (5.9) Confusional State (5.9) Depressed Mood 0 1 (7.1) 0 Depression 2 (10.5) 0 0 Disorientation 0 1 (7.1) 0 Hypervigilance 0 1 (7.1) 0 Libido Decreased 1 (5.3) 0 0 Nervousness (5.9) Sleep Disorder 0 1 (7.1) 0 Dysuria 2 (10.5) 1 (7.1) 0 Micturition Urgency 1 (5.3) 0 0 Pollakiuria 1 (5.3) 0 0 Renal Failure Acute 1 (5.3) 0 0 Dyspareunia (5.9) Vulvovaginal Dryness 1 (5.3) 0 0 Cough 1 (5.3) 0 0 Dyspnoea 2 (10.5) 0 1 (5.9) Dyspnoea Exertional 1 (5.3) 0 1 (5.9) Haemoptysis 1 (5.3) 0 0 Nasal Congestion 1 (5.3) 0 0 Oropharyngeal Pain 0 1 (7.1) 0 Paranasal Sinus Hypersecretion 1 (5.3) 0 0 Productive Cough 1 (5.3) 0 0 Respiratory Tract Congestion 1 (5.3) 0 1 (5.9) 11
13 Sinus Congestion (5.9) Alopecia (5.9) Cold Sweat 0 1 (7.1) 0 Dermatitis Contact 0 1 (7.1) 0 Dry Skin 1 (5.3) 0 0 Dyshidrosis 1 (5.3) 0 0 Puritus Generalized 3 (15.8) 1 (7.1) 0 Skin Odor Abnormal 1 (5.3) 1 (7.1) 0 Urticaria 1 (5.3) 0 0 Flushing 1 (5.3) 0 0 Hot Flush 1 (5.3) 1 (7.1) 0 Hypertension (5.9) 12
Supplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Elter T, Gercheva-Kyuchukova L, Pylylpenko
Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Drug Analysis Print Drug name: RIMONABANT
Jump to first report page Report type: Spontaneous Total number of reactions*: 2123 Total number of ADR reports: 720 Total number of fatal ADR reports: 5 Products included in this print - products (PBGs):
East West Acupuncture & Wellness Center, Inc. Patient Intake Form
East West Acupuncture & Wellness Center, Inc. Patient Intake Form Date: / / How did you hear about us? ( )Ad ( ) Healthcare Referral ( ) Friend/Family Whom may we thank for the referral? Name DOB / / Age
What are you seeking treatment for? Have you ever had acupuncture before? If so, for what condition?
Name Date What are you seeking treatment for? Have you ever had acupuncture before? If so, for what condition? Do you bruise or bleed easily? q Yes q No Pain l r b = left, right, both past current q q
ADULT INTAKE FORM (13 and older) Name Date of First Visit Address City State Zip Code Telephone (home) (work) (cell) Is it ok to leave a message?
ADULT INTAKE FORM (13 and older) Name Date of First Visit Address City State Zip Code Telephone (home) (work) (cell) Is it ok to leave a message? Age Date of Birth Gender Identity Relationship: Single
H E A LT H H I S T O RY
H E A LT H H I S T O RY Name: : List All Current Health Problems: List Any Other Doctors Seen, Treatments And Results Obtained: Your Current Physician(s)/Therapist(s): List All Surgeries And Their s: List
Supplemental Table 1 All Adverse Events Reported with Tolvaptan in North American & Japanese Subjects
Supplemental Table 1 All Adverse Events Reported with Tolvaptan in North American & Japanese Subjects Number of Subjects Reporting AE (%) MedDRA Adverse Event Term 156-05-002 or TEMPO 15/15 mg/day N=17
The dher2 immunotherapeutic consists of recombinant dher2 protein combined with the GSK s proprietary immunostimulant AS15.
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2- overexpressing tumors Steven A. Limentani, Mario Campone, Thierry
Adult Intake. (Please print clearly) Name Date. Address. Address. Home Telephone Number. Emergency contact: Name
Adult Intake (Please print clearly) Name Date Date of birth (M/D/Y) Sex M F Address E-mail Address Home Telephone Number Work _ May we leave messages relating to your visits? Y / N Which Phone Number?
Address: City: State: Zip: Age: Birth Date: Marital Status: M S W D No. of Children. Your Employer: Occupation: Years on Job:
C O N F I D E N T I A L PAT I E N T I N F O R M AT I O N The following information is needed in order to better serve you. Please complete all questions. If you need help, please ask the receptionist.
Divine Medicine NW Greenbrier Parkway, Suite 100 Beaverton, Oregon P F
Divine Medicine 15455 NW Greenbrier Parkway, Suite 100 Beaverton, Oregon 97006 P 503.466.2722 F 503.644.1293 Patient Demographic Information: Patient Name Street Address Last Name First Name Middle Initial
(PLEASE CIRCLE YES ANSWERS ONLY)
(PLEASE CIRCLE YES ANSWERS ONLY) Childhood Illnesses Scarlet Fever Y N Diphtheria Y N Rheumatic fever Y N Mumps Y N Measles Y N German Measles Y N Hospitalizations and Surgery What hospitalizations or
January 2011 NCIC CTG MA.20 (RTOG Endorsed) -1. Opened: December 14, 1999 Closed: February 2, 2007
January 2011 NCIC CTG MA.20 (RTOG Endorsed) -1 NCIC CTG MA.20 (RTOG Endorsed) Protocol Status: Opened: December 14, 1999 Closed: February 2, 2007 Title: A Phase III Study of Regional Radiation Therapy
What is your stress level(1- none 10- very stressful) Occupational Personal
Patient Information form (Please Print) Name: Date of Birth: How do you identify? Male Female Two-spirit Transgendered Intersexed Are you indigenous? If so, please identify Address Postal Code: Phone:
Non Prolotherapy Patient Intake Form
Non Prolotherapy Patient Intake Form Scottsdale Pain Rehabilitation & Wellness Fred G. Arnold, N.M.D. 7595 East McDonald Drive, Suite 100 Scottsdale, AZ 85250 (O) 602 292-2978 Fax: 480-219- 8132 www.prolotherapyphoenix.com
Holly Zapf, ND -- Whole Family Health Clinic
Holly Zapf, ND -- Whole Family Health Clinic 2928 SE Hawthorne, Suite 106, Portland, OR 97214 phone: 503-460-0630 fax: 503-231-4003 wholefamily97214@gmail.com Name: Date: Address: City: State: Zip Code:
Date of Birth Gender. List, in order of importance, your goals for working with your physician:
List, in order of importance, your goals for working with your physician: 1. 2. 3. 4. 5. Please list your allergies and what happens when you are exposed to the allergen: Drug Allergies: Food Allergies:
Premier Pain Consultants
Premier Pain Consultants Advanced Solutions For Pain Relief Name: DOB: Who is your primary care physician/family doctor? What is the major reason you are coming to see the doctor (chief complaint): How
SONG OF NATURAL MEDICINE Dr. Crystal Song, NMD
Patient Intake Form DATE: Patient Name: List in Order of importance what your problems are: 1) 2) 3) DOB: Last time you had wellness checkup and with what physician: Family History Father Mother Siblings
Naturopathic Intake Paperwork
3500 Kensington Ave Suite B- 2 Richmond, VA 23221 T/F 804-977- 2634 Naturopathic Intake Paperwork 1) What led you to choosing this clinic? 2) What do you know about us and how we work? 3) What three expectations
Yen Chiropractic, LLC Personal Injury Patient Intake Form Page 1
GENERAL INFORMATION: TODAY'S DATE: YEN CHIROPRACTIC DR. DANIEL D. YEN, D.C. 4528 W CRAIG RD, SUITE 190 NORTH LAS VEGAS, NV 89032 PATIENT NAME: SOCIAL SECURITY #: ADDRESS: CITY: STATE: ZIP: EMAIL: SEX:
ADULT INTAKE. Name: Date: Address: City: Prov: PC: Telephone (home): (work): Age: Date of Birth: Gender: Female / Male
ADULT INTAKE Name: Date: Address: City: Prov: PC: Telephone (home): (work): Age: Date of Birth: Gender: Female / Male Married: Separated: Divorced: Widowed: Single: Partnership: Live with: Spouse: Partner:
CASE REPORT FORM (April 2012)
CASE REPORT FORM (April 2012) Surveillance of Paediatric Dengue National Paediatric Hospital, Phnom Penh Kingdom of Cambodia Study contact: I am confident that the information supplied in this case record
Dr. Kevin Passero, N.D Lubrano Drive, Suite L 15, Annapolis, MD New Hampshire Ave Suite B4 NW Washington DC 20036
Dr. Kevin Passero, N.D. 443-433-5540 130 Lubrano Drive, Suite L 15, Annapolis, MD 21401 1330 New Hampshire Ave Suite B4 NW Washington DC 20036 Health History Form Name: Date: Address: City: State: Zip
The following information is needed in order to better serve you. Please complete all questions.
C O N F I D E N T I A L PAT I E N T I N F O R M AT I O N The following information is needed in order to better serve you. Please complete all questions. If you need help, please ask the receptionist.
Portland Dental and Naturopathic Clinic
Portland Dental and Naturopathic Clinic Adult Intake Form Name Date of First Visit Address City State Zip Code Telephone # (home) (work) Cell Email address Age Date of Birth Gender: female male Education
Family History. Patient Name: DOB: List in Order of importance what your health concerns are: 1) 2) 3) 4) 5)
Naturopathic Heart Institute of Tucson, LLC June E. Stevens NMD Southwest Integrative Healthcare 2802 N. Alvernon Way, Suite 200 Tucson, AZ 85712 (520) 326-0850 (520) 326-0849 Patient Name: DOB: List in
(Work address): How did you hear about our clinic? Has any other family member already been a patient at the clinic?
Name: Date: Address: City: State: Zip Code: Telephone # (home): (work): E-mail address: Age: Date of Birth: Gender: female male Education: Married: Separated: Divorced: Widowed: Single:_ Partnership:_
Adult Intake - Prenatal
Du La, ND# 1135 Jonah Lusis, ND# 1248 T: 416 598 8898 Adult Intake - Prenatal Date: Name: Age: D.O.B.: Address: City: Postal Code: Telephone: (home) (work) (mobile) E-mail: Emergency contact: Relationship:
Integrative Medicine and Holistic Wellness Center 677 West Main Street Hyannis, MA 02601
Integrative Medicine and Holistic Wellness Center 677 West Main Street Hyannis, MA 02601 Informed Consent for Health Consultation: I herby authorize my practitioner to advise the use of the following therapies.
NAME: LAST FIRST MIDDLE INITIAL ADDRESS CITY STATE ZIP
45 West Crossville Road, Suite 501 Roswell, Georgia 30075 Phone 770-594-1233 Fax 770-594-0037 www.forrestsmithmd.com PERSONAL INFORMATION TODAY S DATE / / NAME: LAST FIRST MIDDLE INITIAL ADDRESS CITY STATE
INTAKE FORM ADULT. Contact Information. Date
INTAKE FORM ADULT Basic Information Dr Aoife M Earls, BSc, MSc Naturopathic Doctor Suite 212, 345 Lakeshore Rd E, Oakville, ON L6H 6K7 1.905.849.6730 draoife.com Date Name Date of Birth YYYY-MM-DD Sex
Charlotte, NC (980) Roanoke, VA (540)
New Patient Information NAME: SEX: / / AGE: (Last) (First) ADDRESS: CITY: STATE: ZIP: HOME PHONE:( ) CELL PHONE: ( ) WORK PHONE: ( ) EMAIL ADDRESS: SSN: Would you like to receive our email newsletter?
NSABP PROTOCOL B-39 RTOG PROTOCOL 0413
NSABP PROTOCOL B-39 RTOG PROTOCOL 0413 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Natural Healing Family Medicine
Adult Intake Form Last Name: First Name: Date: Address: City: State Zip Telephone (Home): Telephone (Work): Email Address: Age: Date of Birth: Gender: Married: Separated: Divorced: Widowed: Single: Partnership:
DR.CRISTINA COLOMA, ND 2888 GARDNER COURT ABBOTSFORD, BC V2T 5H9 Phone/Fax (604)
DR.CRISTINA COLOMA, ND 2888 GARDNER COURT ABBOTSFORD, BC V2T 5H9 Phone/Fax (604) 556-4596 E-mail: abbynaturopath@gmail.com Name: Date: Address: City: Province/State: Zip/Postal Code: Telephone # (home):
Patient Intake Form. Name Date of birth Age Sex: Male Female
Patient Intake Form Today s date: Name Date of birth Age Sex: Male Female Health Concerns: Please list your main health concerns in order of importance. 1. Describe your primary concern When did it start?
Philip J Cimo DDS PA 650 West Bough Lane Ste #160 Houston TX
Philip J Cimo DDS PA 650 West Bough Lane Ste #160 Houston TX 770024 O: (713)464-1887 F: (713)461-0605 PATIENT INFORMATION Date: / / Patient Name: First MI Last Address: Date of Birth: Social Security #:
Autologous Bone Marrow Transplant Crossword Puzzle on Discharge Education. Adult Bone Marrow Transplant Autologous Bone Marrow Transplant Puzzle 1
Autologous Bone Marrow Transplant Crossword Puzzle on Discharge Education 1 Across 1. You will not be able to for at least three months following your transplant. This period may be shorter for patients
c u l t i v a t e w e l l n e s s
Patient Information Name Age Date of birth Sex: Male Female Amy Bader, ND n atu r o p a t h i c d o c t o r Date Address City State Zip Telephone (Home) (Work) (Cell) Email Emergency Contact Relationship
Effects of AG-348, a pyruvate kinase activator, in patients with pyruvate kinase deficiency: Updated results from the DRIVE PK study
S451 Effects of AG-348, a pyruvate kinase activator, in patients with pyruvate kinase deficiency: Updated results from the DRIVE PK study Rachael F Grace* 1, D Mark Layton 2, Frédéric Galactéros 3, Christian
NEW PATIENT INTAKE. Name: Date: Address: Preferred Phone: ( ) Alternate Phone:( ) Leaving Voice Message OK: Y N Preferred method of contact:
NEW PATIENT INTAKE Patient Information: Name: Date: Address: Preferred Phone: ( ) Alternate Phone:( ) Leaving Voice Message OK: Y N Preferred method of contact: E-mail address: Age: Date of Birth: / /
Treatment Intake Form
Sally Valentine, PhD, LCSW 1 W. Camino Real, Suite 202, Boca Raton, FL 33432 drsallyvalentine@me.com 561.391.3305 Treatment Intake Form Please complete all information on this form and bring it to your
APRIL 11-14, 2018 SWOG LYMPHOMA
LYMPHOMA COMMITTEE APRIL 11-14, 2018 SWOG LYMPHOMA 1 CONTENTS S0816 Phase II... 6 S1608 Phase II... 30 EAY131 Master Protocol / Phase II... 32 APRIL 11-14, 2018 SWOG LYMPHOMA 2 Patient Registrations to
Adaptive Play and Wellness. Miela Gruber Cooley ND Registration Form (Please Print)
KIDSPACE Adaptive Play and Wellness 469 Buckland Road South Windsor, CT 06074 phone (860) 432-9923 fax (860) 432-7553 Miela Gruber Cooley ND Registration Form (Please Print) Today s Date: PCP: Patient
Arizona Integrative Medical Solutions 4657 S. Lakeshore Dr, Ste #1 Tempe, AZ
Arizona Integrative Medical Solutions 4657 S. Lakeshore Dr, Ste #1 Tempe, AZ 85282 480-284- 8155 Female Health History Patient Name: Date: DOB: Age: Street Address: City: State: Zip: Home phone: Work Phone:
Hazard Communication & Globally Harmonized System (GHS)
Hazard Communication & Globally Harmonized System (GHS) Introductions Construction Safety Compliance Develop a Common Understanding of: 1. What do You Need to KNOW 2. What do You Need to DO Miscommunicated
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
Published Ahead of Print on May 17, 2018, as doi:10.3324/haematol.2017.171249. Copyright 2018 Ferrata Storti Foundation. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia
Allogeneic Bone Marrow Transplant Crossword Puzzle on Discharge Education
Allogeneic Bone Marrow Transplant Crossword Puzzle on Discharge Education Across 1. If you have, it is important to inform their school that you must be notified of communicable diseases like measles,
Drug Dosage Forms Dr. Stephanie Farrell
Drug Dosage Forms Dr. Stephanie Farrell Introduction Lozenges are solid drug dosage forms containing a drug along with flavoring and sweetening agents. Lozenges are formulated to be harder than ordinary
The Number of symptom/events reported in association with the HPV vaccine broken down by reaction outcome. Not recovered/not resolved
The Number of symptom/events reported in association with the HPV vaccine broken down by reaction outcome Not recovered/not resolved (Reaction) Outcome Recovered/r esolved Recovered/re solved with sequelae
: < : : @ B S : : : HEALTH HISTORY FORM. Patient Name: Birth Date: / / Supportive relationship(s)? Yes No Spiritual Practice? Yes No If yes,
HEALTH HISTORY FORM PERSONAL INFORMATION: Today s Date: Patient Name: Birth Date: / / Supportive relationship(s)? Yes No Spiritual Practice? Yes No If yes, Any pets/farm animals? Yes No If yes, Have you
Dr. Roxie Strand, NMD
Dr. Roxie Strand, NMD Name: Date: Address: City: State: Zip Code: Telephone # home: work: cell: E-mail address: Age: Date of Birth: Gender: female male Education: Married: Separated: Divorced: Widowed:
GPS* Safety Summary for Hydrochloric Acid
GPS* Safety Summary for Hydrochloric Acid Select a Topic: Names Product Overview Manufacture of Product Product Description Product Uses Exposure Potential Health Information Environmental Information
Family members living at home with the patient: Patient s school: Emergency contact: Relationship: Phone:
Nature Cures Naturopathic Clinic Dr. Cathy Picard, Naturopathic Physician 250 Eddie Dowling Hwy., N.Smithfield, RI 02896 Phone: 401-597-0477 Fax: 401-597-0959 www.drcathypicard.com ADOLESCENT INTAKE FORM
SOUTH TEXAS BONE & JOINT
SOUTH TEXAS BONE & JOINT NEW PATIENT INFORMATION (PLEASE PRINT) DATE: PATIENT S NAME EMAIL DATE OF BIRTH AGE M/ F SOCIAL SECURITY # MAILING ADDRESS PERMANENT OR TEMPORARY CITY, STATE, ZIP CODE (AREA CODE)
12/1/17 OUTLINE KEY POINTS ELEMENTS WITH UNSTABLE NUCLEI Radioisotopes and Nuclear Reactions 16.2 Biological Effects of Nuclear Radiation
OUTLINE 16.1 Radioisotopes and Nuclear Reactions 16.2 Biological Effects of Nuclear Radiation PET scan X-ray technology CT scan 2009 W.H. Freeman KEY POINTS Radioactivity is the consequence of an unstable
Broken Arrow Public Schools Physiology Objectives
1 st six weeks 1 Define anatomy and physiology. 2 Compare and contrast levels of structural organization. 3 Identify necessary life functions and essential needs and how they are related to homeostasis.
GPS * Safety Summary for Hydrochloric Acid
GPS * Safety Summary for Hydrochloric Acid Select a Topic: Names Product Overview Manufacture of Product Product Description Product Uses Exposure Potential Health Information Environmental Information
Detection and Identification of Stachybotrys chartarum
Detection and Identification of Stachybotrys chartarum Microbial Volatile Organic Compounds (MVOCs) On-Site Using a Person-Portable Gas Chromatograph/Mass Spectrometer (GC/MS) with a Thermal Desorption
History of Present Illness
Dr. Paul D. Jantzi Brazos Valley Allergy & Asthma Clinics (979) 836-5582 or (800) 362-9633 History of Present Illness Office Visit Date: Time: Location: Patient Name: Primary Physician (PCP): Date of Birth:
Plant and Animal Responses
H Science Name period date assigned date due date returned Directions: Using the laminated cards, match the story to its symptoms and cause. ill in the correct cause and symptoms for each effect in the
Removing Heavy Metals and Toxins From Our Bodies Has Been a Challenge Until Now...
Any information presented here is not to be understood as 'professional advice'. Warning: If You Are Concerned About Heavy Metals in your body, Here is Vital Information For You... Your health, even your
Toxic Algae and Cyanobacteria in Recreational Waters. Rang Cho Miriam Moritz
Toxic Algae and Cyanobacteria in Recreational Waters Rang Cho Miriam Moritz Algae Large, diverse group of eukaryotic organisms Contain chlorophyll and/or other pigments green, brown or red colour Perform
Arizona Integrative Medical Solutions 4657 S. Lakeshore Dr, Ste #1 Tempe, AZ
Arizona Integrative Medical Solutions 4657 S. Lakeshore Dr, Ste #1 Tempe, AZ 85282 480-284-8155 Diabetic Health History Patient Name: Date: DOB: Age: Street Address: City: State: Zip: Home phone: Work
MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy
MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy Richard Finkel, MD 1, ; Krista Vandenborne, PT, PhD. 2, H Lee Sweeney, PhD. 2,
Supplementary Online Content
Supplementary Online Content Sellers MM, Keele LJ, Sharoky CE, Wirtalla C, Bailey EA, Kelz RR. Association of surgical practice patterns and clinical outcomes with surgeon training in university- or nonuniversity-based
Personal Health Choices
Personal Health Choices University of Nevada Las Vegas Center for Health Information Analysis & Nevada Department of Health and Human Services Division of Health Care Financing and Policy BOOK 2 SPECIALTY
Lesson U4C2L8 FIT Questions
Lesson U4C2L8 FIT Questions 1. (U4C2L8:F1) How motivated are you to study cold weather injuries? A) I am very motivated since I spend a lot of time in the cold. B) I am fairly motivated and am sure it
Personal Health Choices
Personal Health Choices University of Nevada Las Vegas Center for Health Information Analysis & Nevada Department of Health and Human Services Division of Health Care Financing and Policy BOOK 2 SPECIALTY
Phone number: When and how did your pain begin? (a date is required for Medicare and some insurance policies) Date of onset:
C H I R O P R A C T I C O R T H O P E D I C S A N D R E H A B I L I T A T I O N ILJXAi Pain Relief Clinics Please complete all sections. Full Name: Nickname: Gender: M F Age: Race: Date of Birth: I I Family
A SIX MONTH OLD GIRL WITH HEMOLYTIC ANEMIA Case study by Jim Perkins, M.D. ( 2009)
A SIX MONTH OLD GIRL WITH HEMOLYTIC ANEMIA Case study by Jim Perkins, M.D. ( 2009) CLINICAL PRESENTATION A six month old girl presented with lethargy after four days of cough, rhinorrhea, and fever, and
Comprehensive Health Report
1 Comprehensive Health Report Report Prepared By; Team Cyber Astro 2 Dear XYZ Please find our analysis for your complete Comprehensive Health Report. We thank you for giving us this opportunity to analyse
Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB
Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB Bruce D. Given, M.D. COO, Arrowhead Pharmaceuticals Science of HBV Cure 2018 June 8, 2018 Safe Harbor Statement This
Infant/Children Assessment sheet Medical- Surgical unit/ ICU
King Saud University Nursing college Maternity & Child Health Nursing Department NUR 327 Infant/Children Assessment sheet Medical- Surgical unit/ ICU Date: / / Date Received: / / ( ) On Time ( ) Late Student
BIOS 2083: Linear Models
BIOS 2083: Linear Models Abdus S Wahed September 2, 2009 Chapter 0 2 Chapter 1 Introduction to linear models 1.1 Linear Models: Definition and Examples Example 1.1.1. Estimating the mean of a N(μ, σ 2
Introduction Chpt 1. Study Slides
Introduction Chpt 1 Study Slides A group of molecules working together toward a common function is a: A. Cell B. Atom C. Organelle D. Tissue E. Organ ANSWER A group of molecules working together toward
S0819 Phase III. Coordinating Group: SWOG
S0819 Phase III Coordinating Group: SWOG A Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/ with or without Concurrent Cetuximab in Patients with Advanced Non-Small
Risk Assessment of Staphylococcus aureus and Clostridium perfringens in ready to eat Egg Products
Risk Assessment of Staphylococcus aureus and Clostridium perfringens in ready to eat Egg Products Introduction Egg products refer to products made by adding other types of food or food additives to eggs
Chronic Granulomatous Disease Medical Management
Chronic Granulomatous Disease Medical Management N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t
COORDINATOR TIPS Verna Brown, CEM. EM Coordinator. Severe Storm
Severe Storm Severe thunder storms are very likely here in Washington County and can cause lots of damage. Lightning strikes can lead to fires, medical problems, and power outages. They may occur singly,
COOK ISLANDS TE MARAE ORA
COOK ISLANDS MINISTRY OF HEALTH TE MARAE ORA ANNUAL STATISTICAL TABLES HEALTH STATISTICAL TABLES 2008-2010 MEDICAL RECORDS UNIT Rarotonga Hospital It should be noted that information contained in this
Lab Standard/Hazard Communication Training. MTU Dept. of Chemistry November 17, 2006
Lab Standard/Hazard Communication Training MTU Dept. of Chemistry November 17, 2006 Lab Standard/HazComm Lab Standard vs. Hazard Communication Who is required to have training: Under OSHA, the term worker
Hierarchical Time-series Modelling for Haemodialysis. Tingting Zhu 24 th October 2016
Hierarchical Time-series Modelling for Haemodialysis Tingting Zhu 24 th October 2016 Content Background on haemodialysis Methods o Gaussian Process Regression (GPR) o Hierarchical Gaussian Process Regression
In a small time t: BMR; BMR BMR BMR BMR BMR The brain constitutes only 2.5% of body weight, but is responsible for 20% of the BMR (dreams). It requires a fair amount of oxygen consumption. Weight
Analysis of Longitudinal Data. Patrick J. Heagerty PhD Department of Biostatistics University of Washington
Analysis of Longitudinal Data Patrick J Heagerty PhD Department of Biostatistics University of Washington Auckland 8 Session One Outline Examples of longitudinal data Scientific motivation Opportunities
Fairfield Public Schools Science Curriculum. Draft Units
Fairfield Public Schools Science Curriculum Draft Units Human Anatomy and Physiology - Blood, Guts, Senses, and Defenses 1 Human Anatomy and Physiology - Blood, Guts, Senses, and Defenses: Description
Biometeorological Study on the Relationship between Weather and Chronic Disease-Possibility of Weather Forecasting for Health and Disease
59 Biometeorological Study on the Relationship between Weather and Chronic Disease-Possibility of Weather Forecasting for Health and Disease Yoshitaka FUKUOKA 1*, Ken-ichi KIDA 2 and Ryoji MIYASHITA 3
Heat and Cold in Medicine
Heat and Cold in Medicine Physical Basis of Heat and Temperature Matter is composed of molecules that are in motion, In gas or liquid the molecules move about hitting one another or the walls of the container;
Srdan Verstovsek, MD, PhD Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Efficacy and Safety of Pegylated Interferon Alpha- 2a in Patients with Essential Thrombocythemia (ET) and Polycythemia vera (PV): Results after a Median 7-year Follow-up of a Phase 2 Study Srdan Verstovsek,
These are just basic training slides, may vary from standards. Basic First Aid. 1
These are just basic training slides, may vary from standards Basic First Aid www.askmaaz.com 1 What is 1 st Aid First Aid is an immediate and temporary care given to a victim of an accident or sudden
Online supplement. Absolute Value of Lung Function (FEV 1 or FVC) Explains the Sex Difference in. Breathlessness in the General Population
Online supplement Absolute Value of Lung Function (FEV 1 or FVC) Explains the Sex Difference in Breathlessness in the General Population Table S1. Comparison between patients who were excluded or included
Pharmacognosy Lab. Senna s Advantages : Used for patients who aren t responsive for milder laxatives Senna s Disadvantages :
Pharmacognosy Lab Lab1,2,3 Comparative determination of glycosides in Senna using different methods of extraction ( Soxhlet, Maceration, & Ultrasonic bath ) Senna s Advantages : I. Used as Stimulant Laxative
Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines
Abstract #O17 Effects of Sofosbuvir/Ribavirin Treatment and ITPA Phenotype on Endogenous Purines Leah C. Jimmerson, Carolyn W. Clayton, Samantha MaWhinney, Eric G. Meissner, Zayani Sims, Shyamasundaran
Lesson Plan: Explore. Materials. Exploration. Medical Terminology. The items below are needed for this exercise: Form: Terminology Word Search
Medical Terminology Lesson Plan: Explore Materials Objectives: Use medical terminology to indicate anatomical structures. Identify word parts, including root, prefix, and suffix. Interpret medical terms.
A Clinical Trial Simulation System, Its Applications, and Future Challenges. Peter Westfall, Texas Tech University Kuenhi Tsai, Merck Research Lab
A Clinical Trial Simulation System, Its Applications, and Future Challenges Peter Westfall, Texas Tech University Kuenhi Tsai, Merck Research Lab Acknowledgement Major collaborators Stephan Ogenstand,
HEAT ACCLIMATIZATION GUIDE
HEAT ACCLIMATIZATION GUIDE H E AT A C C L I M AT I Z AT I O N G U I D E 2003 RANGER & AIRBORNE SCHOOL STUDENTS u Should you be concerned about hot weather? u How fast can you become heat acclimatized?